-
1
Figure S1 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Pubblicazione 2025Altri autori: “...Helen Gandler (15054017)...”
-
2
Figure S3 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Pubblicazione 2025Altri autori: “...Helen Gandler (15054017)...”
-
3
Figure S4 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Pubblicazione 2025Altri autori: “...Helen Gandler (15054017)...”
-
4
Figure S2 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Pubblicazione 2025Altri autori: “...Helen Gandler (15054017)...”
-
5
Figure S6 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Pubblicazione 2025Altri autori: “...Helen Gandler (15054017)...”
-
6
Figure S5 from Targeting MET and FGFR in Relapsed or Refractory Acute Myeloid Leukemia: Preclinical and Clinical Findings, and Signal Transduction Correlates
Pubblicazione 2025Altri autori: “...Helen Gandler (15054017)...”